ERBB2 and breast cancer: In preclinical studies, oral dosing of TAS-117 in murine xenograft models of gastric cancer (NCI-N87; HER2 amplification) and breast cancer (KPL-4; HER2 amplification, PIK3CA mutation) has demonstrated single-agent antitumor activity and was well tolerated [20].